As of Friday close, Edwards Lifesciences Corporation’s (NYSE:EW) stock was down -$0.52, moving down -0.74 percent to $69.66. The average number of shares traded per day over the past five days has been 3,284,860 shares. 3 times new highs have been achieved over the past 5 days, with a -$3.54 fall in that time frame. In the last twenty days, the average volume was 3,161,870, while in the previous 50 days, it was 3,378,764.
Since last month, EW stock retreated -8.22%. Shares of the company fell to $69.53 on 09/22/23, the lowest level in the past month. A 52-week high of $94.87 was reached on 06/30/23 after having rallying from a 52-week low of $67.13. Since the beginning of this year, EW’s stock price has dropped by -6.63% or -$4.95, and marked a new high 20 times. However, the stock has declined by -26.57% since its 52-week high.
EW stock investors should be aware that Edwards Lifesciences Corporation (EW) stock had its last reported insider trading activity 9 days ago on Sep 14. Wood Larry L, the Global President TAVR & Surg of the company, disposed of 8,660 shares for $73.63 on Sep 14. It resulted in a $637,615 divestment by the insider. BOBO DONALD E JR sold 4,500 shares at an average price of $73.71 on Sep 14. The insider now owns 39,503 shares following the transaction. On Sep 08, CVP, Critical Care Szyman Catherine M. sold 5,000 shares at $76.00 apiece. The transaction was valued at $380,000.
Valuation Metrics
Right now, Edwards Lifesciences Corporation (EW) has a P/E ratio of about 30.86. The stock’s beta is 1.05. Besides these, the trailing price-to-sales (P/S) ratio of 7.57, the price-to-book (PB) ratio of 6.63, and the price-to-cash flow ratio of 62.79 may also be considered.
Financial Health
In the three months ended June 29, Edwards Lifesciences Corporation’s quick ratio stood at 2.30, while its current ratio was 3.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.09, and the total debt-to-equity ratio was 0.09. On the profitability front, the trailing twelve-month gross margin is 79.10% percent. In the year ended June 29, EBITDA margin amounted to 34.73%, whereas operating margins totaled 27.70%. Based on annual data, EW earned $4.3 billion in gross profit and brought in $5.38 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 23.50%. Return on equity (ROE) for the past 12 months was 22.80%.
In Edwards Lifesciences Corporation’s quarter-end financial report for June 29, it reported total debt of $596.7 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. EW’s revenue rose 10.21% to $1.46 billion during the quarter, while net income inched up to $1.53 billion. While analysts expected Edwards Lifesciences Corporation to report $0.65 quarterly earnings, the actual figure was $0.66 per share, beating the consensus estimate by 1.50%. During the quarter, the company generated $363.3 million in EBITDA. The liabilities of Edwards Lifesciences Corporation were 2.56 billion at the end of its most recent quarter ended June 29, and its total debt was $684.5 million. The value of shareholders’ equity is $607.92 million.
Technical Picture
This quick technical analysis looks at Edwards Lifesciences Corporation’s (EW) price momentum. With a historical volatility rate of 15.43%, the RSI 9-day stood at 19.91% on 22 September.
With respect to its five-day moving average, the current Edwards Lifesciences Corporation price is down by -4.84% percent or -$3.54. At present, EW shares trade -7.13% below its 20-day simple moving average and -20.43% percent below its 100-day simple moving average. However, the stock is currently trading approximately -25.17% below its SMA50 and -5.67% below its SMA200.
Stochastic coefficient K was 2.42% and Stochastic coefficient D was 7.97%, while ATR was 1.49. Given the Stochastic reading of 1.65% for the 14-day period, the RSI (14) reading has been calculated as 24.36%. As of today, the MACD Oscillator reading stands at -1.79, while the 14-day reading stands at -2.94.
Analyst Ratings
Robert W. Baird launched its rating on Edwards Lifesciences Corporation (NYSE: EW) to an Outperform in a note to investors on July 19, 2023. Edwards Lifesciences Corporation (EW) has been rated Overweight by analysts. According to 0 brokerage firms, EW is a sell, and 13 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 3 analysts rate Edwards Lifesciences Corporation stock as buy, with 13 recommending it as overweight.
With a median target price of $99.00, the current consensus forecast for the stock is $75.00 – $110.00. Based on these forecasts, analysts predict Edwards Lifesciences Corporation (EW) will achieve an average price target of $96.88.
